| Larotrectinib studied in …STUDIED_INderived20 of 20show fewer |
|---|
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 20 trials list this drug (15 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07843550Phase 1/Phase 2 · not yet recruiting A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy · 20 trials list this drug (15 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06390852Phase 2 · active not recruiting Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) · 20 trials list this drug (15 active) | — | — | Lymphoma,Malignant Solid Neoplasm,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03155620Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) · 20 trials list this drug (15 active) | — | — | Hepatoblastoma,Malignant Germ Cell Tumor,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04142437recruiting Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body · 20 trials list this drug (15 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04945330recruiting NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes · 20 trials list this drug (15 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02576431Phase 2 · completed A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors · 20 trials list this drug (15 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03213704Phase 2 · active not recruiting Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) · 20 trials list this drug (15 active) | — | — | Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor,Hepatoblastoma,Malignant Germ Cell Tumor+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06563999Phase 2 · recruiting Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. · 20 trials list this drug (15 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04879121Phase 2 · recruiting Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors · 20 trials list this drug (15 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04655404early Phase 1 · recruiting A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion · 20 trials list this drug (15 active) | — | — | Diffuse Intrinsic Pontine Glioma,High-Grade Glioma, NOS | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02122913Phase 1 · completed A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer · 20 trials list this drug (15 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03834961Phase 2 · active not recruiting Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia · 20 trials list this drug (15 active) | — | — | Solid Neoplasm,Central Nervous System Neoplasm,Acute Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02637687Phase 1/Phase 2 · active not recruiting A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children · 20 trials list this drug (15 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07010393Phase 4 · not yet recruiting Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study · 20 trials list this drug (15 active) | — | — | Thyroid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05236257completed A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database · 20 trials list this drug (15 active) | — | — | Infantile Fibrosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06482086Phase 2 · recruiting Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer · 20 trials list this drug (15 active) | — | — | Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05192642completed A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice · 20 trials list this drug (15 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05725200Phase 2 · recruiting Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer · 20 trials list this drug (15 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03025360approved for marketing Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion · 20 trials list this drug (15 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |